Powered by

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

BERKELEY HEIGHTS, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the publication of a peer-reviewed journal article featuring the company's cyclin dependent kinase 2/9 (CDK2/9) inhibitors. In an article published in the Journal of National Cancer Institute (JNCI), preclinical data demonstrated that both Cyclacel's CYC065, a second-generation, clinical stage, CDK2/9 inhibitor, and CCT68127, a pr

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox